[Current therapeutic strategies for diffuse large B‑cell lymphoma].

Area of Science:

• Oncology
• Hematology
• Immunology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin's lymphoma.
• The addition of rituximab to CHOP chemotherapy (R-CHOP) has dramatically improved patient survival rates.
• Current treatment strategies often rely on the International Prognostic Index (IPI) for risk stratification.

Purpose of the Study:

• To review the impact of rituximab on DLBCL treatment outcomes.
• To explore the significance of gene expression profiling in classifying DLBCL subtypes (GC type vs. ABC type).
• To identify novel therapeutic targets for improved DLBCL management.

Main Methods:

• Review of clinical outcomes in DLBCL patients treated with and without rituximab.
• Analysis of gene expression profiles to differentiate DLBCL subtypes.
• Identification of molecular targets based on subtype-specific pathogenesis.

Main Results:

• Rituximab incorporation has led to a substantial decrease in DLBCL mortality compared to the pre-rituximab era.
• Gene expression profiling distinguishes between germinal center B-cell (GC) and activated B-cell (ABC) types of DLBCL.
• Understanding these subtypes has revealed critical molecules for DLBCL growth, presenting new therapeutic targets.

Conclusions:

• Further advancements in DLBCL treatment are expected through targeted therapies based on molecular subtypes.
• Incorporating novel agents into R-CHOP regimens or substituting existing drugs may further enhance survival and reduce toxicity.
• Personalized treatment approaches for DLBCL are becoming increasingly feasible.